A retrospective observational investigation conducted at Shanxi Bethune Hospital has demonstrated that metagenomic next-generation sequencing of bronchoalveolar lavage fluid significantly improves the identification of lower respiratory tract pathogens in patients with connective tissue diseases. Clinicians evaluating individuals who suffer from systemic autoimmune disorders frequently encounter severe respiratory deterioration that poses a diagnostic dilemma between underlying autoimmune pulmonary involvement and active infectious processes. In this clinical cohort of eighty-one hospitalized patients presenting with new or progressive pulmonary lesions on high-resolution computed tomography, metagenomic next-generation sequencing achieved an overall pathogen detection rate of 77.7 percent, which proved markedly superior to the 45.7 percent positivity rate documented using conventional microbiological testing methods. Multidisciplinary clinical teams subsequently utilized these genomic findings in conjunction with radiographic features, inflammatory markers, and microbiological comparators to establish definitive diagnoses, thereby illustrating the capability of high-throughput sequencing assays to illuminate complex microbiological profiles in severely ill, immunosuppressed individuals.
Connective tissue diseases represent a heterogeneous spectrum of immune-mediated chronic inflammatory disorders that frequently target pulmonary structures, contributing substantially to overall patient morbidity and mortality. Therapeutic management for these disorders typically necessitates sustained administration of high-dose systemic glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs, and targeted biological therapies. This dual insult—comprising inherent disease-related immune dysregulation coupled with pharmacologically induced immunosuppression—severely compromises host antimicrobial defenses and leaves individuals uniquely vulnerable to opportunistic respiratory pathogens. Compounding this clinical vulnerability, active lower respiratory tract infections often manifest radiographically as diffuse bilateral infiltrates or ground-glass opacities that closely mirror autoimmune-driven parenchymal exacerbations, rendering timely etiological discrimination essential for instituting appropriate targeted therapies while avoiding catastrophic clinical deterioration.
Traditional microbiological workflows rely heavily on targeted culture isolation, serological antibody assays, and pathogen-specific polymerase chain reaction panels, each of which presents inherent clinical constraints when managing immunocompromised hosts. Routine microbial cultures frequently require prolonged incubation periods, maintain narrow coverage spectra, and demonstrate poor diagnostic sensitivity when encountering fastidious bacteria, atypical organisms, or patients already receiving empirical antimicrobial treatments. In contrast, metagenomic next-generation sequencing offers an unbiased, culture-independent modality capable of directly extracting, sequencing, and bioinformatically analyzing total microbial nucleic acids present within clinical specimens. By evaluating bronchoalveolar lavage fluid collected during bronchoscopy within seventy-two hours of patient admission, standardized high-throughput sequencing workflows bypass the prerequisite for predefined microbial targets.
The study cohort comprised eighty-one hospitalized patients exhibiting a median age of fifty-seven years and an interquartile range extending from forty-seven to sixty-seven years, with women accounting for 62.9 percent of the total population. Analysis of underlying rheumatic diagnoses revealed that idiopathic inflammatory myopathies, rheumatoid arthritis, and systemic lupus erythematosus represented the predominant systemic disorders, complemented by cases of antineutrophil cytoplasmic antibody-associated vasculitis, Sjögren’s syndrome, adult-onset Still’s disease, systemic sclerosis, mixed connective tissue disease, Behçet’s disease, relapsing polychondritis, and polymyalgia rheumatica. Prior to enrollment, 74.0 percent of patients had documented exposures to systemic glucocorticoids, 59.2 percent were receiving disease-modifying antirheumatic drugs, and 23.4 percent had undergone biologic therapies. Interstitial lung disease affected 48.1 percent of the entire cohort, with predominant baseline clinical symptoms comprising cough in 55.3 percent, shortness of breath in 54.3 percent, fever in 37.0 percent, and severe dyspnea in 32.1 percent of individuals.
Comparative microbiological evaluations confirmed a statistically significant diagnostic advantage for metagenomic next-generation sequencing over conventional laboratory testing across every major microbiological kingdom. Among the eighty-one enrolled patients, metagenomic sequencing identified thirty-five distinct pathogen species, encompassing eighteen bacterial species, seven fungal species, and ten viral species. In contrast to conventional testing, which achieved an overall detection rate of only 45.7 percent, metagenomic sequencing attained an overall positivity rate of 77.7 percent. When categorized by pathogen classes, the bacterial detection rate for sequencing reached 55.6 percent compared with 25.9 percent for standard cultures, fungal detection reached 50.6 percent compared with 17.3 percent for conventional fungal assays, and viral identification reached 59.3 percent compared with standard serological and targeted polymerase chain reaction methods. These differences highlights the technical capability of unbiased sequencing to capture microbial signatures that escape routine diagnostic detection.
Analysis of fungal pathogens demonstrated that Pneumocystis jirovecii constituted the single most prevalent fungal organism identified via sequencing, detected in twenty-four patients representing 29.6 percent of the total cohort, followed by Aspergillus fumigatus in 7.4 percent. The viral spectrum revealed by sequencing was similarly broad, most prominently featuring Epstein-Barr virus in 14.8 percent and cytomegalovirus in 8.6 percent of patients. While standard viral testing was restricted to serum IgM panels and targeted polymerase chain reaction for specific herpesviruses, metagenomic sequencing captured a broader range of viral activity. The authors noted that distinguishing low-level viral reactivation from active clinical disease remains challenging in heavily immunosuppressed patients, underscoring the necessity of interpreting viral sequence reads within the overall clinical context.
The bacterial spectrum detected by metagenomic sequencing exhibited distinctive epidemiological features compared with previously published cohorts of connective tissue disease patients. While earlier literature frequently highlighted Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae as primary Gram-negative pathogens, the present study observed Enterococcus faecium in eight cases, Klebsiella pneumoniae in seven cases, and Nocardia species in five cases. The relatively frequent isolation of Nocardia is of notable clinical significance, as nocardiosis primarily afflicts severely immunocompromised individuals and carries documented one-year mortality rates approaching twenty-five percent. Because Nocardia organisms demand prolonged incubation periods, specialized staining procedures, and specific nutrient media, conventional cultures frequently miss these infections. Metagenomic sequencing additionally identified fastidious or difficult-to-culture bacteria such as Streptococcus pneumoniae, Haemophilus species, and Tropheryma whipplei, which have rarely been captured in comparable cohorts evaluated by standard microbiological protocols.
Polymicrobial infections constituted a major hallmark of respiratory disease in this cohort, with mixed infections documented in 65.2 percent of the sixty-six patients definitively classified as having pulmonary infections. Coinfection patterns involving bacterial, fungal, and viral agents simultaneously represented the most common configuration, occurring in nineteen patients, while bacterial-viral coinfections appeared in nine patients and bacterial-fungal coinfections occurred in eight patients. Viruses served as the most frequent copathogens across mixed infection profiles. When comparing patients who tested positive by both methods against those who were positive by sequencing alone, investigators found that double-positive patients exhibited significantly higher erythrocyte sedimentation rates and procalcitonin levels, significantly lower serum albumin concentrations, lower PaO2/FiO2 ratios, and a lower baseline prevalence of interstitial lung disease, suggesting that conventional tests primarily detect cases with higher pathogen loads and more overt systemic inflammatory responses.
Methodological concordance analyses revealed limited overall diagnostic agreement between metagenomic next-generation sequencing and conventional microbiological testing, yielding a Cohen’s kappa coefficient of 0.368. Forty-two patients tested positive by both diagnostic modalities, twenty-one were positive solely by sequencing, three tested positive exclusively by conventional methods, and fifteen yielded negative results on both assays. Among the forty-two concordantly positive patients, complete pathogen-level agreement occurred in only 11.9 percent of cases, whereas partial matching occurred in 35.7 percent and complete mismatching was observed in 52.4 percent. Using conventional testing as the microbiological comparator, metagenomic sequencing achieved a positive percent agreement of 93.3 percent and a negative percent agreement of 41.7 percent. Integration of sequencing data into multidisciplinary clinical reviews prompted therapeutic adjustments in 78.6 percent of patients, facilitating an increase in effective pathogen coverage from 45.5 percent during initial empirical treatment to 89.4 percent following targeted regimen optimization.
Negative sequencing results also provided actionable guidance for differential diagnosis and patient management among fifteen individuals ultimately classified as having non-infectious autoimmune pulmonary involvement. Following the integration of negative sequencing data with clinical features and imaging, clinicians successfully discontinued unnecessary empirical antimicrobial therapies in ten patients, while intensifying immunosuppressive therapies through methylprednisolone pulse regimens, additional immunosuppressive agents, or Janus kinase inhibitors. The authors noted that because their investigation employed a single-center retrospective design without an external control group, the observed therapeutic modifications and short-term survival outcomes cannot be definitively attributed to sequencing alone, concluding that prospective, multicenter controlled trials remain necessary to establish long-term clinical efficacy.
Subject of Research: Diagnostic performance of bronchoalveolar lavage fluid metagenomic sequencing in connective tissue disease patients
Article Title: Diagnostic value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in connective tissue diseases patients with suspected pulmonary infection
Article References: Cui, Y., Ma, D., Hou, R., Liu, Y., Liu, Y., Xu, K., & Zhang, L. (2026). Diagnostic value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in connective tissue diseases patients with suspected pulmonary infection. Frontiers in Cellular and Infection Microbiology, 16, Article 1768383. https://doi.org/10.3389/fcimb.2026.1768383
Image Credits: AI Generated
DOI: 10.3389/fcimb.2026.1768383
Keywords: metagenomic next-generation sequencing, connective tissue diseases, bronchoalveolar lavage fluid, pulmonary infection, conventional microbiological testing, interstitial lung disease, opportunistic pathogens, Pneumocystis jirovecii, Diagnostic, value, bronchoalveolar, lavage
News Source: Kristina Jarvis. (November 10, 2026). Lung Fluid Sequencing Improves Pathogen Detection in Connective Tissue Disease Patients. Scienmag.



